Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- WBA -15.8%, LEVI -15.5% (also increases dividend), AVAV -6%, MU -5.7%, JEF -5.6% (also increases dividend), LNN -2.8%, AYI -1.6%, NG -1.5%, MLKN -1%
Other news:
- RXRX -18.9% (prices offering of 30,769,230 shares of common stock at $6.50 per share)
- IP -13.9% (Suzano (SUZ) formalizes that it will not pursue a transaction involving the acquisition of International Paper)
- GRFS -10% (Moody's Ratings downgraded Grifols' rating to B3 from B2 and its probability of default rating (PDR) to B3-PD from B2-PD)
- ADUS -8.7% (prices offering of 1.5 mln shares of common stock at $108.00 per share)
- ELAN -8.2% (announced updates to the expected FDA approval timelines for Zenrelia and Credelio Quattro; 2024 Innovation sales guidance increased)
- CTRI -4.3% (CEO to step down to become CEO at AEP)
- STLA -3.5% (completes second tranche of 2024 share buyback program)
- KTB -2.7% (in sympathy with weak LEVI earnings)
- PVH -2% (in sympathy with weak LEVI earnings)
- GS -1.9% (several banks reacting to Fed Stress Test results)
- WDC -1.7% (in sympathy with weak MU earnings)
- GSK -1.7% (CDC recommends adults 60+ may receive single dose of RSV vaccine)
- NVDA -1.6% (in sympathy with weak MU earnings)
- CARE -1.5% (released statement regarding the dismissal of lawsuits filed by WV Governor Jim Justice and related entities)
- WFC -1.4% (several banks reacting to Fed Stress Test results)
- USB -1.4% (several banks reacting to Fed Stress Test results)
- SM -1.4% (announces highly accretive $2.0 billion Uinta Basin acquisition, 11% increase to fixed dividend and reloaded $500 million share repurchase program)
- OXM -1.1% (in sympathy with weak LEVI earnings)
- CHWY -1% (announces $500 million repurchase of shares from BC Partners)